艾媒咨询 | 2025年中国医用分子筛制氧行业发展白皮书

需求增长驱动医用分子筛制氧市场扩容，技术创新将推动行业向智能化、绿色化、高端化迈进。iiMedia Research（艾媒咨询）数据显示，2024年中国医用分子筛制氧机市场规模约4.25亿元，预计2029年将进一步攀升至7.06亿元。随着人口老龄化的加剧、公众健康意识的提高，以及医疗需求的增加，中国医用分子筛制氧机市场的规模在稳步扩大。同时，国家对医疗健康产业的重视程度不断提升，加之环保和新能源等领域的发展，医用分子筛制氧机在工业、医疗和家用等多个领域的应用正不断拓展。
Demand growth drives the expansion of the medical molecular sieve oxygen production market, and technological innovation will promote the industry to become intelligent, green and high-end. iiMedia Research data show that in 2024, the market size of China's medical molecular sieve oxygen generator is about 425 million yuan, and it is expected to further climb to 706 million yuan in 2029. With the increasing aging of the population, the improvement of public health awareness and the increase of medical demand, the scale of China's medical molecular sieve oxygen generator market is steadily expanding. At the same time, the state's attention to the medical and health industry continues to improve, coupled with the development of environmental protection and new energy and other fields, medical molecular sieve oxygen generator in industrial, medical and household applications are constantly expanding.

艾媒咨询｜2022年中国幽门螺旋杆菌检测市场专题调查报告

美国将幽门螺杆菌被列为明确致癌物后，幽门螺杆菌在中国受到了极大的关注。iiMedia Research（艾媒咨询）数据显示，2021年中国幽门螺杆菌检测市场规模73.1亿元，预计2022年将达到86.6亿元。艾媒咨询分析师认为，随着大众的健康意识逐渐加强，幽门螺杆菌自测产品将成为必需品，幽门螺杆菌检测市场发展空间广阔。而幽门螺杆菌自测产品的上市，有助于推动居家检测。(《艾媒咨询｜2022年中国幽门螺旋杆菌检测市场专题调查报告》完整高清PDF版共23页，可点击文章底部报告下载按钮进行报告下载)
After the United States Department of Health & Human Services listed Helicobacter pylori as a definitive carcinogen, Helicobacter pylori received great attention in China. According to data from iiMedia Research, the market size of Helicobacter pylori testing in China will be 7.31 billion yuan in 2021 and is expected to reach 8.66 billion yuan in 2022. With increasing health awareness, Helicobacter pylori self-test product is necessary for people. The market for Helicobacter pylori self-test product is vast. The launch of Helicobacter pylori self-test products helps to promote home testing.（“iiMedia Report ｜Investigation Report on The Market of Helicobacter Pylori Testing in China in 2022”full version has 23 pages, please click the Browse HD Report button on the right side of the article to browse the report）

艾媒咨询|2021年中国夜间用药年度观察报告

本报告涉及的案例/品牌/企业：美团买药，叮当快药

在众多社会服务中，夜间用药成为人们最关注的夜间社会服务之一，近年来，各地相关行政管理机构也陆续出台相关扶持政策，鼓励商家上线夜间送药平台、发展24小时药店，提供夜间送药服务，推动解决“夜间买药难”问题。近日，iiMedia Research(艾媒咨询)最新发布《2021年中国夜间用药年度观察报告》，基于2021年初至2021年末的监测数据，对中国夜间用药市场持续追踪。报告显示，年初有61.2%的用户夜间生病选择忍，而年底这一数字降至52.1%，据推算年末夜间用药受益群体新增约4000万人。报告指出，日渐成熟的中国外卖送药平台，成为解决夜间用药的重要参与者。通过一年的发展，在美团买药“小黄灯”计划等24小时药店惠民工程的推动下，线上24小时药店数量增加、夜间买药配送速度更快、服务保障更加成熟，用户知晓度有了较大提升，夜间买药难的问题得到有效缓解。
Among many social services，night medication has become one of the night social services that people pay most attention to. In recent years，relevant administrative agencies around the country have also successively issued relevant support policies to encourage businesses to launch night medication delivery platforms，develop 24-hour pharmacies，provide night medication delivery services， and promote the solution of the problem of "difficulty in buying drugs at night". Recently， iiMedia Research released the annual observation report on nighttime medication in China in 2021，which continuously tracks China's nighttime medication market based on the monitoring data from the beginning of 2021 to the end of 2021. The report shows that at the beginning of the year， 61.2% of users chose to tolerate illness at night，while at the end of the year，the figure fell to 52.1%. It is estimated that about 40 million people will benefit from night medication at the end of the year.The report points out that the increasingly mature Chinese takeout delivery platform has become an important participant in solving the problem of night medication. Through one year's development，driven by the 24-hour pharmacy benefit project such as the "small yellow light" plan of meituan drug purchase， the number of online 24-hour pharmacies has increased，the speed of drug purchase and distribution at night is faster，the service guarantee is more mature，the user awareness has been greatly improved，and the problem of difficult drug purchase at night has been effectively alleviated.

艾媒咨询|2021年9月中国医疗健康行业投融资数据分析报告

人口老龄化，人均GDP、人均收入的提升，同时也带来了人们健康需求的增长。近年来，医疗健康产业创新不断涌现，并发展成为最活跃的行业之一，相关细分赛道也维持着较高的增长，收获了资本市场的大量关注。
艾媒咨询通过艾媒数据中心(data.iimedia.cn)查询并发布《2021年9月中国医疗健康行业投融资数据分析简报》，助力投资人与创业者用户即时了解市场趋势，获取关键投资决策所需的数据，把握投资逻辑和最新产业机会。(《艾媒咨询|2021年9月中国医疗健康行业投融资数据分析报告》完整高清PDF版共21页，可点击文章底部报告下载按钮进行报告下载)
The aging of population and the increase of per capita GDP and per capita income have also brought about the growth of people's health demand. In recent years, the innovation of medical and health industry has been emerging and developed into one of the most active industries. The relevant segments have also maintained high growth and gained a lot of attention from the capital market.
Iimedia inquires and publishes the analysis briefing on investment and financing data of “China's medical and health industry in September 2021 through iimedia data center (data. Iimedia. cn), so as to help investors and entrepreneurs understand the market trend in real time, obtain the data required for key investment decisions, and grasp the investment logic and the latest industrial opportunities.(“iiMedia Report |Analysis report on investment and financing data of China's medical and health industry in September 2021”full version has 21 pages in total, please click the Browse HD Report button on the right side of the article to browse the report)